Hyperglycemia in Diabetes Drives Hepatic Fibrosis Through the Non-Enzymatic Function of HK2 and AGEs-mediated Matrix Stiffening

Abstract

Diabetes is implicated in accelerating the progression of hepatic fibrosis, and empagliflozin (an SGLT2 inhibitor) has potential therapeutic effects on diabetic hepatic fibrosis. However, their underlying mechanisms are still largely uncharacterized.

The paper